19 results on '"Andrea Schöler"'
Search Results
2. Antiproliferation and Antiencystation Effect of Class II Histone Deacetylase Inhibitors on Acanthamoeba castellanii
- Author
-
Ki-Back Chu, Hae-Ahm Lee, Marc Pflieger, Fabian Fischer, Yodita Asfaha, Leandro A. Alves Avelar, Alexander Skerhut, Matthias U. Kassack, Finn K Hansen, Andrea Schöler, Thomas Kurz, Min-Jeong Kim, Eun-Kyung Moon, and Fu-Shi Quan
- Subjects
Infectious Diseases - Published
- 2022
3. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
- Author
-
Laura Sinatra, Jing Yang, Julian Schliehe-Diecks, Niklas Dienstbier, Melina Vogt, Philip Gebing, Luisa M. Bachmann, Melf Sönnichsen, Thomas Lenz, Kai Stühler, Andrea Schöler, Arndt Borkhardt, Sanil Bhatia, and Finn K. Hansen
- Subjects
Ubiquitin-Protein Ligases ,Drug Discovery ,Proteolysis ,Molecular Medicine ,Antineoplastic Agents ,Histone Deacetylase 6 ,Solid-Phase Synthesis Techniques ,Proteolysis Targeting Chimera ,Cell Proliferation - Abstract
Selective histone deacetylase 6 (HDAC6) inhibitors are useful tools to study the function of the second catalytic domain of HDAC6, but they cannot interfere with (non)-enzymatic functions of HDAC6, which are mediated via the first catalytic domain or the ubiquitin binding domain. In this work, we utilized the proteolysis targeting chimera (PROTAC) technology to achieve the chemical knock-down of HDAC6. Two series of cereblon-recruiting PROTACs were synthesized via a solid-phase parallel synthesis approach, which allowed the rapid preparation of two HDAC6 degrader mini libraries. The PROTACs were either based on an unselective vorinostat-like HDAC ligand or derived from a selective HDAC6 inhibitor. Notably, both PROTAC series demonstrated selective degradation of HDAC6 in leukemia cell lines. The best degraders from each series (denoted A6 and B4) were capable of degrading HDAC6 via ternary complex formation and the ubiquitin−proteasome pathway, with DC50 values of 3.7 and 13.3 nM, respectively. Moreover, HDAC6 degradation of A6 and intracellular (nucleocytoplasmic) localization of a fluorescein-labelled PROTAC (A7) was determined by fluorescence microscopy. PROTAC A6 demonstrated promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines. These findings highlight the potential of this series of degraders as effective pharmacological tools for the targeted degradation of HDAC6.
- Published
- 2022
4. Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity
- Author
-
Andrea Schöler, Thomas Kurz, Sanil Bhatia, Jing Yang, Nadine Horstick-Muche, Finn K. Hansen, Alexandra Hamacher, Melf Sönnichsen, Arndt Borkhardt, Marc Pflieger, Matthias U. Kassack, and Julian Schliehe-Diecks
- Subjects
Cell Survival ,Leukaemia cell ,Antineoplastic Agents ,Pharmacology ,Histone Deacetylase 6 ,Hydroxamic Acids ,01 natural sciences ,Biochemistry ,Pathogenesis ,Structure-Activity Relationship ,Cell Line, Tumor ,inhibitors ,Drug Discovery ,medicine ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,Patient compliance ,Cell Proliferation ,Dose-Response Relationship, Drug ,Molecular Structure ,Full Paper ,010405 organic chemistry ,Chemistry ,Phenylurea Compounds ,Organic Chemistry ,Cancer ,Biological activity ,Full Papers ,HDAC6 ,HDAC isozyme profile ,medicine.disease ,0104 chemical sciences ,Histone Deacetylase Inhibitors ,Molecular Docking Simulation ,010404 medicinal & biomolecular chemistry ,Leukemia ,leukaemia ,Molecular Medicine ,Drug Screening Assays, Antitumor ,Selectivity ,histone deacetylases - Abstract
The acetylome is important for maintaining the homeostasis of cells. Abnormal changes can result in the pathogenesis of immunological or neurological diseases, and degeneration can promote the manifestation of cancer. In particular, pharmacological intervention in the acetylome with pan‐histone deacetylase (HDAC) inhibitors is clinically validated. However, these drugs exhibit an undesirable risk‐benefit profile due to severe side effects. Selective HDAC inhibitors might promote patient compliance and represent a valuable opportunity in personalised medicine. Therefore, we envisioned the development of HDAC6‐selective inhibitors. During our lead structure identification, we demonstrated that an alkoxyurea‐based connecting unit proves to be beneficial for HDAC6 selectivity and established the synthesis of alkoxyurea‐based hydroxamic acids. Herein, we report highly potent N‐alkoxyurea‐based hydroxamic acids with improved HDAC6 preference compared to nexturastat A. We further validated the biological activity of these oxa analogues of nexturastat A in a broad subset of leukaemia cell lines and demonstrated their superior anti‐proliferative properties compared to nexturastat A., A hydroxylamine connecting unit facilitates HDAC6 preference: The derivatization of nexturastat A with alkoxyurea connecting units is reported. This modification resulted in an increased preference for HDA6 and increased antiproliferative properties in haematological cancer cell lines.
- Published
- 2021
5. Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile
- Author
-
Christoph Selg, Andrea Schöler, Finn K. Hansen, Maria Hanl, Menyhárt B. Sárosi, Sanil Bhatia, Evamarie Hey-Hawkins, Laura Sinatra, Arndt Borkhardt, and Julian Schliehe-Diecks
- Subjects
biology ,Chemistry ,General Chemistry ,HDAC6 ,Combinatorial chemistry ,Solid-phase synthesis ,Histone ,biology.protein ,Moiety ,Carborane ,Histone deacetylase ,Pharmacophore ,Selectivity - Abstract
The elevated expression of histone deacetylases (HDACs) in various tumor types renders their inhibition an attractive strategy for epigenetic therapeutics. One key issue in the development of improved HDAC inhibitors (HDACis) is the selectivity for single HDAC isoforms over unspecific pan inhibition to minimize off-target toxicity. Utilizing the carborane moiety as a fine-tuning pharmacophore, we herein present a robust solid phase synthetic approach towards tailor-made HDACis meeting both ends of the selectivity spectrum, namely pan inhibition and highly selective HDAC6 inhibition., This work describes a versatile solid phase synthesis of carborane-capped histone deacetylase inhibitors with a tunable selectivity profile and synergistic anticancer activity with bortezomib.
- Published
- 2021
6. Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
- Author
-
Luisa M. Bachmann, Maria Hanl, Felix Feller, Laura Sinatra, Andrea Schöler, Jens Pietzsch, Markus Laube, and Finn K. Hansen
- Subjects
solid-phase synthesis ,HDAC ,Chemistry (miscellaneous) ,Organic Chemistry ,Drug Discovery ,COX ,cancer ,Molecular Medicine ,Pharmaceutical Science ,Physical and Theoretical Chemistry ,multi-target drugs ,Analytical Chemistry - Abstract
Multi-target drugs (MTDs) are emerging alternatives to combination therapies. Since both histone deacetylases (HDACs) and cyclooxygenase-2 (COX-2) are known to be overexpressed in several cancer types, we herein report the design, synthesis, and biological evaluation of a library of dual HDAC-COX inhibitors. The designed compounds were synthesized via an efficient parallel synthesis approach using preloaded solid-phase resins. Biological in vitro assays demonstrated that several of the synthesized compounds possess pronounced inhibitory activities against HDAC and COX isoforms. The membrane permeability and inhibition of cellular HDAC activity of selected compounds were confirmed by whole-cell HDAC inhibition assays and immunoblot experiments. The most promising dual inhibitors, C3 and C4, evoked antiproliferative effects in the low micromolar concentration range and caused a significant increase in apoptotic cells. In contrast to previous reports, the simultaneous inhibition of HDAC and COX activity by dual HDAC-COX inhibitors or combination treatments with vorinostat and celecoxib did not result in additive or synergistic anticancer activities.
- Published
- 2023
7. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
- Author
-
Finn K. Hansen, Alexandra Hamacher, Jens Meiler, Jan J. Bandolik, Martin Roatsch, Clara T. Schoeder, Andrea Schöler, Laura Sinatra, Sanil Bhatia, Matthias U. Kassack, Melf Sönnichsen, and Arndt Borkhardt
- Subjects
MULTITARGET DRUGS ,solid-phase synthesis ,Dual targeting ,DNA damage ,Antineoplastic Agents ,Apoptosis ,Caspase 3 ,Hydroxamic Acids ,010402 general chemistry ,01 natural sciences ,Histone Deacetylases ,Catalysis ,PROTAC ,Chimera (genetics) ,Solid-phase synthesis ,Cell Line, Tumor ,Humans ,POLYPHARMACOLOGY ,Multi‐Target Drugs | Hot Paper ,Molecular Structure ,biology ,010405 organic chemistry ,Chemistry ,Communication ,TEMOZOLOMIDE ,General Chemistry ,Anticancer drug ,Communications ,multi-target drugs ,0104 chemical sciences ,Cell biology ,Histone Deacetylase Inhibitors ,Resins, Synthetic ,Histone ,histone deacetylase ,biology.protein ,Histone deacetylase - Abstract
Inhibition of more than one cancer‐related pathway by multi‐target agents is an emerging approach in modern anticancer drug discovery. Here, based on the well‐established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series of alkylating HDACi using a pharmacophore‐linking strategy. For the parallel synthesis of the target compounds, we developed an efficient solid‐phase‐supported protocol using hydroxamic acids immobilized on resins (HAIRs) as stable and versatile building blocks for the preparation of functionalized HDACi. The most promising compound, 3 n, was significantly more active in apoptosis induction, activation of caspase 3/7, and formation of DNA damage (γ‐H2AX) than the sum of the activities of either active principle alone. Furthermore, to demonstrate the utility of our preloaded resins, the HAIR approach was successfully extended to the synthesis of a proof‐of‐concept proteolysis‐targeting chimera (PROTAC), which efficiently degrades histone deacetylases., Hydroxamic acids immobilized on resins (HAIRs) were developed and utilized for the library synthesis of DNA‐alkylating HDAC inhibitors and a proof‐of‐concept HDAC degrader (PROTAC). A hybrid compound based on the pharmacophores of chlorambucil and panobinostat was identified as the most promising chimeric HDAC inhibitor and demonstrated improved anticancer properties compared to the sum of the activities of either pharmacophore alone.
- Published
- 2020
8. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs
- Author
-
Finn K. Hansen, Jens Meiler, Martin Roatsch, Andrea Schöler, Laura Sinatra, Melf Sönnichsen, Arndt Borkhardt, Alexandra Hamacher, Clara T. Schoeder, Jan J. Bandolik, Sanil Bhatia, and Matthias U. Kassack
- Subjects
Dual target ,Solid-phase synthesis ,Biochemistry ,DNA damage ,Chemistry ,General Medicine ,Histone deacetylase - Published
- 2020
9. Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
- Author
-
Linda Schäker‐Hübner, Reza Haschemi, Thomas Büch, Fabian B. Kraft, Birke Brumme, Andrea Schöler, Robert Jenke, Jens Meiler, Achim Aigner, Gerd Bendas, and Finn K. Hansen
- Subjects
Histone Deacetylase Inhibitors ,Pharmacology ,Peptoids ,Organic Chemistry ,Drug Discovery ,Molecular Medicine ,Histone Deacetylase 1 ,General Pharmacology, Toxicology and Pharmaceutics ,Biochemistry ,Histone Deacetylases - Abstract
Herein we report the structure-activity and structure-physicochemical property relationships of a series of class I selective ortho-aminoanilides targeting the "foot-pocket" in HDAC12. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI-994) and evaluated their solubility, lipophilicity (log D
- Published
- 2022
10. Multicomponent Synthesis, Binding Mode, and Structure–Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups
- Author
-
David W. Christianson, Finn K. Hansen, Andrea Schöler, Alexander Jan Skerhut, Julian Schliehe-Diecks, Sanil Bhatia, Melf Sönnichsen, Arndt Borkhardt, Matthias U. Kassack, Julia Hauer, Jeremy D. Osko, and Nina Reßing
- Subjects
Daunorubicin ,Tetrazoles ,Antineoplastic Agents ,Plasma protein binding ,Histone Deacetylase 6 ,01 natural sciences ,Article ,Bortezomib ,Structure-Activity Relationship ,03 medical and health sciences ,Cell Line, Tumor ,Drug Discovery ,medicine ,Animals ,Humans ,Structure–activity relationship ,Cytotoxicity ,Epirubicin ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Molecular Structure ,Drug Synergism ,HDAC6 ,3. Good health ,0104 chemical sciences ,Histone Deacetylase Inhibitors ,010404 medicinal & biomolecular chemistry ,Enzyme ,chemistry ,Microsomes, Liver ,Proteasome inhibitor ,Cancer research ,Molecular Medicine ,Drug Screening Assays, Antitumor ,Protein Binding ,medicine.drug - Abstract
Histone deacetylase 6 (HDAC6) is an emerging target for the treatment of cancer, neurodegenerative diseases, inflammation, and other diseases. Here, we present the multicomponent synthesis and structure-activity relationship of a series of tetrazole-based HDAC6 inhibitors. We discovered the hit compound NR-160 by investigating the inhibition of recombinant HDAC enzymes and protein acetylation. A cocrystal structure of HDAC6 complexed with NR-160 disclosed that the steric complementarity of the bifurcated capping group of NR-160 to the L1 and L2 loop pockets may be responsible for its HDAC6-selective inhibition. While NR-160 displayed only low cytotoxicity as a single agent against leukemia cell lines, it augmented the apoptosis induction of the proteasome inhibitor bortezomib in combination experiments significantly. Furthermore, a combinatorial high-throughput drug screen revealed significantly enhanced cytotoxicity when NR-160 was used in combination with epirubicin and daunorubicin. The synergistic effect in combination with bortezomib and anthracyclines highlights the potential of NR-160 in combination therapies.
- Published
- 2020
11. Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs
- Author
-
Lukas von Bredow, Thomas Martin Schäfer, Julian Hogenkamp, Maik Tretbar, Daniel Stopper, Fabian B. Kraft, Julian Schliehe-Diecks, Andrea Schöler, Arndt Borkhardt, Sanil Bhatia, Jana Held, and Finn K. Hansen
- Subjects
histone deacetylase ,artemisinin ,multitarget drugs ,parasitic diseases ,Drug Discovery ,histone deacetylase, artemisinin, multitarget drugs ,Pharmaceutical Science ,Molecular Medicine ,ddc:610 - Abstract
Artemisinin-based combination therapies (ACTs) are the gold standard for the treatment of malaria, but the efficacy is threatened by the development of parasite resistance. Histone deacetylase inhibitors (HDACis) are an emerging new class of potential antiplasmodial drugs. In this work, we present the design, synthesis, and biological evaluation of a mini library of dihydroartemisinin–HDACi hybrid molecules. The screening of the hybrid molecules for their activity against selected human HDAC isoforms, asexual blood stage P. falciparum parasites, and a panel of leukemia cell lines delivered important structure–activity relationships. All synthesized compounds demonstrated potent activity against the 3D7 and Dd2 line of P. falciparum with IC50 values in the single-digit nanomolar range. Furthermore, the hybrid (α)-7c displayed improved activity against artemisinin-resistant parasites compared to dihydroartemisinin. The screening of the compounds against five cell lines from different leukemia entities revealed that all hydroxamate-based hybrids (7a–e) and the ortho-aminoanilide 8 exceeded the antiproliferative activity of dihydroartemisinin in four out of five cell lines. Taken together, this series of hybrid molecules represents an excellent starting point toward the development of antimalarial and antileukemia drug leads.
- Published
- 2021
12. Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE
- Author
-
Nathalie Erdeljac, Ryan Gilmour, Finn K. Hansen, Kathrin Bussmann, and Andrea Schöler
- Subjects
010405 organic chemistry ,Stereochemistry ,medicine.drug_class ,Drug discovery ,Organic Chemistry ,Histone deacetylase inhibitor ,01 natural sciences ,Biochemistry ,HDAC1 ,In vitro ,0104 chemical sciences ,3. Good health ,010404 medicinal & biomolecular chemistry ,chemistry.chemical_compound ,chemistry ,Drug Discovery ,medicine ,Potency ,Histone deacetylase ,Bioisostere ,Vorinostat ,medicine.drug - Abstract
[Image: see text] A chiral, hybrid bioisostere of the CF(3) and Et groups (BITE) was installed in a series of vorinostat (Zolinza) analogues, and their histone deacetylase (HDAC) inhibitory behavior was studied relative to that of their nonfluorinated counterparts. Several of these compounds containing the 1,2-difluoroethylene unit showed in vitro potency greater than that of the clinically approved drug itself against HDAC1. This trend was found to be general with the BITE-modified HDAC inhibitors performing significantly better than the ethyl derivatives. Installed by the direct, catalytic vicinal difluorination of terminal alkenes using an I(I)/I(III) manifold, this underexplored chiral bioisostere shows potential in drug discovery.
- Published
- 2019
13. Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity
- Author
-
Alexander Schramm, Holger Gohlke, Christoph G. W. Gertzen, Thomas Kurz, Andrea Schöler, Nina Reßing, Viktoria Marquardt, Finn K. Hansen, Marc Remke, and Achim Aigner
- Subjects
Medizin ,Pharmaceutical Science ,01 natural sciences ,Biochemistry ,chemistry.chemical_compound ,Neuroblastoma ,Drug Discovery ,medicine ,IC50 ,Vorinostat ,Pharmacology ,010405 organic chemistry ,Organic Chemistry ,Peptoid ,HDAC6 ,medicine.disease ,HDAC1 ,0104 chemical sciences ,Chemistry ,010404 medicinal & biomolecular chemistry ,chemistry ,Docking (molecular) ,Cancer research ,Molecular Medicine ,Histone deacetylase ,medicine.drug - Abstract
Histone deacetylases (HDACs) have been identified as promising epigenetic drug targets for the treatment of neuroblastoma and glioblastoma. In this work, we have rationally designed a novel class of peptoid-based histone deacetylase inhibitors (HDACi). A mini library of β-peptoid-capped HDACi was synthesized using a four-step protocol. All compounds were screened in biochemical assays for their inhibition of HDAC1 and HDAC6 and docking studies were performed to rationalize the observed selectivity profile. The synthesized compounds were further examined for tumor cell-inhibitory activity against a panel of neuroblastoma and glioblastoma cell lines. In particular, non-selective compounds with potent activity against HDAC1 and HDAC6 showed strong antiproliferative effects. The most promising HDACi, compound 6i, displayed submicromolar tumor cell-inhibitory potential (IC(50): 0.21–0.67 μM) against all five cancer cell lines investigated and exceeded the activity of the FDA-approved HDACi vorinostat.
- Published
- 2019
14. One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites
- Author
-
Yevgeniya Antonova-Koch, Andrea Schöler, Tamirat Gebru, Finn K. Hansen, Vicky M. Avery, Thomas Kurz, Daniela Diedrich, Eva Hesping, Jana Held, Elizabeth A. Winzeler, Katharina Stenzel, Sandra Duffy, Stephan Meister, Gillian M. Fisher, and Katherine T. Andrews
- Subjects
0301 basic medicine ,Plasmodium falciparum ,030106 microbiology ,Protozoan Proteins ,Pharmacology ,Plasmodium ,Article ,Histones ,Antimalarials ,Peptoids ,03 medical and health sciences ,chemistry.chemical_compound ,parasitic diseases ,Drug Discovery ,Gametocyte ,medicine ,Humans ,Malaria, Falciparum ,IC50 ,biology ,Drug discovery ,Organic Chemistry ,Acetylation ,Peptoid ,Hep G2 Cells ,General Medicine ,biology.organism_classification ,medicine.disease ,3. Good health ,Histone Deacetylase Inhibitors ,030104 developmental biology ,chemistry ,Histone deacetylase ,Malaria - Abstract
Malaria drug discovery has shifted from a focus on targeting asexual blood stage parasites, to the development of drugs that can also target exo-erythrocytic forms and/or gametocytes in order to prevent malaria and/or parasite transmission. In this work, we aimed to develop parasite- selective histone deacetylase inhibitors (HDACi) with activity against the disease-causing asexual blood stages of Plasmodium malaria parasites as well as with causal prophylactic and/or transmission blocking properties. An optimized one-pot, multi-component protocol via a sequential Ugi four-component reaction and hydroxylaminolysis was used for the preparation of a panel of peptoid-based HDACi. Several compounds displayed potent activity against drug- sensitive and drug-resistant P. falciparum asexual blood stages, high parasite-selectivity and submicromolar activity against exo-erythrocytic forms of P. berghei. Our optimization study resulted in the discovery of the hit compound 1u which combines high activity against asexual blood stage parasites (Pf 3D7 IC(50): 4 nM; Pf Dd2 IC(50): 1 nM) and P. berghei exo-erythrocytic forms (Pb EEF IC(50): 25 nM) with promising parasite-specific activity (SI(Pf 3D7/HepG2): 2496, SI(Pf Dd2/HepG2): 9990, and SI(Pb EEF/HepG2): 400).
- Published
- 2018
15. Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity
- Author
-
Finn K. Hansen, Yevgeniya Antonova-Koch, Marcel K. W. Mackwitz, Andrea Schöler, Elizabeth A. Winzeler, Katherine T. Andrews, Eva Hesping, Korina Eribez, and Jana Held
- Subjects
Drug ,media_common.quotation_subject ,Plasmodium falciparum ,Pharmacology ,01 natural sciences ,03 medical and health sciences ,chemistry.chemical_compound ,Antimalarials ,Mice ,Structure-Activity Relationship ,In vivo ,Drug Discovery ,Animals ,Humans ,Cytotoxicity ,IC50 ,030304 developmental biology ,media_common ,0303 health sciences ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Peptoid ,General Medicine ,In vitro ,0104 chemical sciences ,Histone Deacetylase Inhibitors ,Histone ,biology.protein ,Histone deacetylase - Abstract
Histone deacetylases (HDACs) have been identified as emerging antiplasmodial drug targets. In this work, we report on the synthesis, structure-activity relationships, metabolic stability and in vivo efficacy of new peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity. A mini library of HDAC inhibitors was synthesized using a one-pot, multi-component protocol or submonomer pathways. The screening of the target compounds for their activity against asexual blood stage parasites, human cell cytotoxicity, liver stage parasites, and selected human HDAC isoforms provided important structure-activity relationship data. The most promising HDAC inhibitor from this series, compound 3n, demonstrated potent activity against drug-sensitive and drug-resistant asexual stage P. falciparum parasites and was selective for the parasite versus human cells (Pf3D7 IC50 0.016 μM; SIHepG2/Pf3D7 573; PfDd2 IC50 0.002 μM; SIHepG2/PfDd2 4580) combined with activity against P. berghei exoerythrocytic liver stages (PbEEF IC50 0.48 μM). While compound 3n displayed high stability in human (Clint 5 μL/min/mg) and mouse (Clint 6 μL/min/mg) liver microsomes, only modest oral in vivo efficacy was observed in P. berghei infected mice. Together these data provide a foundation for future work to improve the properties of these dual-stage inhibitors as drug leads for malaria.
- Published
- 2020
16. Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors
- Author
-
Andrea Schöler, Marcel K. W. Mackwitz, David W. Christianson, Matthias U. Kassack, Alexandra Hamacher, Jana Held, Jeremy D. Osko, and Finn K. Hansen
- Subjects
0301 basic medicine ,Denticity ,Pyridines ,Danio ,Histone Deacetylase 6 ,01 natural sciences ,Biochemistry ,Article ,Catalysis ,03 medical and health sciences ,chemistry.chemical_compound ,Pyridine ,Animals ,Physical and Theoretical Chemistry ,Zebrafish ,Biological evaluation ,Molecular Structure ,biology ,010405 organic chemistry ,Organic Chemistry ,Imidazoles ,Zebrafish Proteins ,HDAC6 ,biology.organism_classification ,Combinatorial chemistry ,0104 chemical sciences ,Histone Deacetylase Inhibitors ,030104 developmental biology ,chemistry ,Histone deacetylase - Abstract
The multicomponent synthesis of a mini-library of histone deacetylase inhibitors with imidazo[1,2- a]pyridine-based cap groups is presented. The biological evaluation led to the discovery of the hit compound MAIP-032 as a selective HDAC6 inhibitor with promising anticancer activity. The X-ray structure of catalytic domain 2 from Danio rerio HDAC6 complexed with MAIP-032 revealed a monodentate zinc-binding mode.
- Published
- 2018
17. Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics
- Author
-
Andor Krizsan, Hermann Kalwa, Finn K. Hansen, Robert Nowotny, René Thieme, Holger Gohlke, Andrea Schöler, Ines Gockel, Christoph G. W. Gertzen, and Rick Raudszus
- Subjects
Fluorophore ,Clinical Biochemistry ,Pharmaceutical Science ,Antineoplastic Agents ,Histone Deacetylase 1 ,Histone Deacetylase 6 ,Biochemistry ,Histones ,chemistry.chemical_compound ,Peptoids ,Cell Line, Tumor ,Drug Discovery ,Fluorescence microscope ,Humans ,Molecular Biology ,Cell Proliferation ,Fluorescent Dyes ,Dansyl Compounds ,Hydroxamic acid ,Microscopy, Confocal ,Organic Chemistry ,Peptoid ,Biological activity ,Acetylation ,Histone Deacetylase Inhibitors ,Molecular Docking Simulation ,chemistry ,Microscopy, Fluorescence ,Docking (molecular) ,Drug Design ,Molecular Medicine ,Histone deacetylase ,Pharmacophore ,Protein Binding - Abstract
Fluorescent tagging of bioactive molecules is a powerful tool to study cellular uptake kinetics and is considered as an attractive alternative to radioligands. In this study, we developed fluorescent histone deacetylase (HDAC) inhibitors and investigated their biological activity and cellular uptake kinetics. Our approach was to introduce a dansyl group as a fluorophore in the solvent-exposed cap region of the HDAC inhibitor pharmacophore model. Three novel fluorescent HDAC inhibitors were synthesized utilizing efficient submonomer protocols followed by the introduction of a hydroxamic acid or 2-aminoanilide moiety as zinc-binding group. All compounds were tested for their inhibition of selected HDAC isoforms, and docking studies were subsequently performed to rationalize the observed selectivity profiles. All HDAC inhibitors were further screened in proliferation assays in the esophageal adenocarcinoma cell lines OE33 and OE19. Compound 2, 6-((N-(2-(benzylamino)-2-oxoethyl)-5-(dimethylamino)naphthalene)-1-sulfonamido)-N-hydroxyhexanamide, displayed the highest HDAC inhibitory capacity as well as the strongest anti-proliferative activity. Fluorescence microscopy studies revealed that compound 2 showed the fastest uptake kinetic and reached the highest absolute fluorescence intensity of all compounds. Hence, the rapid and increased cellular uptake of 2 might contribute to its potent anti-proliferative properties.
- Published
- 2019
18. Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity
- Author
-
Tamirat Gebru Woldearegai, Andrea Schöler, Yevgeniya Antonova-Koch, Mary Clarke, Daniela Diedrich, Eva Hesping, Thomas Kurz, Jana Held, Marcel K. W. Mackwitz, Finn K. Hansen, Tina S. Skinner-Adams, Laura Limbach, Katherine T. Andrews, and Elizabeth A. Winzeler
- Subjects
Drug ,Plasmodium berghei ,media_common.quotation_subject ,Plasmodium falciparum ,Drug resistance ,01 natural sciences ,Biochemistry ,Article ,Histones ,chemistry.chemical_compound ,Inhibitory Concentration 50 ,Peptoids ,Structure-Activity Relationship ,Cell Line, Tumor ,Drug Discovery ,Animals ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,media_common ,Pharmacology ,biology ,010405 organic chemistry ,Organic Chemistry ,Peptoid ,Acetylation ,biology.organism_classification ,0104 chemical sciences ,Histone Deacetylase Inhibitors ,010404 medicinal & biomolecular chemistry ,Histone ,chemistry ,Toxicity ,biology.protein ,Molecular Medicine ,Histone deacetylase ,Dual stage - Abstract
Novel malaria intervention strategies are of great importance due to the development of drug resistance in malaria endemic countries. In this regard, histone deacetylases (HDACs) have emerged as new and promising malaria drug targets. In this work, we present the design, synthesis and biological evaluation of 20 novel HDAC inhibitors with antiplasmodial activity. Based on a previously discovered peptoid-based hit compound, we modified all regions of the peptoid scaffold by utilizing a one-pot multicomponent pathway and submonomer routes to gain a deeper understanding of the structure-activity as well as structure-toxicity relationships. Most compounds displayed potent activity against asexual blood stage P. falciparum parasites with IC(50) values ranging from 0.0052–0.25 µM and promising selectivity over mammalian cells (SI(Pf3D7/HepG2): 170–1483). In addition, several compounds showed encouraging submicromolar activity against P. berghei exo-erythrocytic forms (PbEEF). Our study led to the discovery of the hit compound (N-(2-(benzylamino)-2-oxoethyl)-N-(4-(hydroxycarbamoyl)benzyl)-4-i-propylbenzamide, 2h) as a potent and parasite-specific dual-stage antiplasmodial HDAC inhibitor (IC(50) (Pf3D7) = 0.0052 µM, IC(50) (PbEEF) = 0.016 µM).
- Published
- 2018
19. Front Cover: Structure–Activity and Structure–Toxicity Relationships of Peptoid‐Based Histone Deacetylase Inhibitors with Dual‐Stage Antiplasmodial Activity (ChemMedChem 9/2019)
- Author
-
Tamirat Gebru Woldearegai, Thomas Kurz, Laura Limbach, Katherine T. Andrews, Mary Clarke, Daniela Diedrich, Eva Hesping, Marcel K. W. Mackwitz, Andrea Schöler, Yevgeniya Antonova-Koch, Finn K. Hansen, Jana Held, Elizabeth A. Winzeler, and Tina S. Skinner-Adams
- Subjects
Pharmacology ,biology ,Chemistry ,Organic Chemistry ,Peptoid ,Plasmodium falciparum ,biology.organism_classification ,Biochemistry ,chemistry.chemical_compound ,Front cover ,Drug Discovery ,Toxicity ,Molecular Medicine ,Histone deacetylase ,General Pharmacology, Toxicology and Pharmaceutics ,Dual stage - Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.